2.54
-0.24
(-8.65%)
May 20 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 2.52 - 2.79 |
| 52 week | 0.65 - 4.49 |
| Open | 2.78 |
| Vol / Avg. | 1.97M/1.13M |
| Mkt cap | 4.40M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.01* |
| Shares | 173.74M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Apr 8, 2013
Interim 2012-2013 Evocutis PLC Earnings Release
|
|
Key stats and ratios
| Q3 (Jul '12) | 2012 | |
| Net profit margin | -1014.16% | -332.39% |
| Operating margin | -1115.93% | -373.52% |
| EBITD margin | - | -175.49% |
| Return on average assets | -84.28% | -51.73% |
| Return on average equity | -91.14% | -56.75% |
| Employees | 16 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Evocutis plc is engaged in the provision of skin microbiology and clinical dermatology services to companies in pharmaceutical and consumer healthcare markets, using the Company�s living skin technology, LabSkin. The three main areas of the Company�s activity include Specialist skin microbiology research and products, such as SYN1113; Skin microbiology laboratory services to support Clinical Research Organisations, and development of LabSkin and its use for contract research with sponsor companies and its direct sale as a research product. The Company offer combination of contract research services to dermatology researchers and product developers. Its contract research and consultancy services include Skin Microbiology; Microbiology to support clinical studies and Research using its Living Skin Equivalent Model (LabSkin).
Officers and directors
| Gwyn O. Humphreys | Interim Chief Executive Officer, Executive Director | |
| J. Darren Bamforth | Chief Financial Officer, Group Finance Director, Company Secretary, Executive Director | |
| Richard A. Bojar | Chief Scientist | |
| Thomas Bannatyne | Non-Executive Chairman of the Board | |
| Michael C.N. Townend | Non-Executive Director |